Abstract
While clinically relevant copy number variants (CNVs) occur in 6-8% of pregnancies with fetal structural anomalies, they are typically difficult to detect via noninvasive prenatal screening (NIPS) because of the low fetal fraction in maternal cell-free DNA (cfDNA). By leveraging fetal fraction amplification, a method to preferentially sequence shorter fragments that are enriched for fetal-derived cfDNA, we can detect small CNVs with high sensitivity. Here we describe an analytical validation of an NIPS that can detect clinically relevant CNVs across the genome.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
